Among three UPR branches, the PERK/eIF2α axis is most well studied as a potential therapeutic target to mitigate symptoms in neurodegenerative conditions such as Alzheimer’s disease (Halliday et al. 2017; Ohno 2018; Rozpędek-Kamińska et al. 2020; Smedley et al. 2021). This evidence concerns the gene EIF2A and early-onset autosomal dominant Alzheimer disease.